SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 or 15d-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

 

 

Report on Form 6-K dated January 24, 2007

(Commission File No. 1-15024)

This Report on Form 6-K shall be incorporated by reference in our Registration Statements on Form F-3 as filed with the Commission on May 11, 2001 (File No. 333-60712) and our Registration Statements on Form S-8 as filed with the Commission on September 5, 2006 (File No. 333-137112) and on October 1, 2004 (File No. 333-119475), in each case to the extent not superseded by documents or reports subsequently filed by us under the Securities Act of 1933 or the Securities Exchange Act of 1934, in each case as amended

 


 

Novartis AG

(Name of Registrant)

 

Lichtstrasse 35

4056 Basel

Switzerland

(Address of Principal Executive Offices)

 


 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F: x      Form 40-F: o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Yes: o      Nox

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Yes: o      Nox

Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

 

Yes: o      Nox

Enclosure:             Novartis AG Announces Results for the Fourth Quarter and Full Year of 2006

 


 

 

Novartis International AG

 

Novartis Global Communications

 

CH-4002 Basel

 

Switzerland

 

 

 

http://www.novartis.com

 

 

 

 

MEDIA RELEASE   •   COMMUNIQUE AUX MEDIAS   •   MEDIENMITTEILUNG

 

Novartis strategic healthcare portfolio drives sustained strong performance with record full-year results in 2006

 

                  Dynamic 2006 Group performance:

 

                  Net sales rise 15% (+14% in local currencies) to USD 37.0 billion

 

                  Operating income advances 18% as productivity initiatives more than offset acquisition costs and investments in new pharmaceutical product launches

 

                  Net income up 17% to USD 7.2 billion

 

                  EPS rise 16% to USD 3.06 per share in the fifth consecutive year of double-digit profit expansion

 

                  Excluding Chiron acquisition-related charges, Group operating income climbs 28% and net income up 25%

 

                  Dividend proposed to shareholders for 2006 of CHF 1.35 per share, a 17% increase from 2005 and representing the tenth consecutive year of a higher payment

 

                  Recent acquisitions and plans to divest Medical Nutrition strengthen strategic focus on healthcare portfolio

 

                  Novartis preparing for multiple new product launches in 2007-2008, led by Exforge and Tekturna/Rasilez (hypertension), Galvus (diabetes) and Lucentis (blindness)

 

Key Group figures

 

Full year

 

 

 

2006

 

2005

 

% Change

 

 

 

 

 

 

 

 

 

 

 

USD m

 

% of
net sales

 

USD m

 

% of
net sales

 

USD

 

lc

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net sales

 

37 020

 

 

 

32 212

 

 

 

15

 

14

 

Operating income

 

8 174

 

22.1

 

6 905

 

21.4

 

18

 

 

 

Net income

 

7 202

 

19.5

 

6 141

 

19.1

 

17

 

 

 

Basic earnings per share/ADS

 

USD

3.06

 

 

 

USD

2.63

 

 

 

16

 

 

 

 

Fourth quarter

 

 

 

Q4 2006

 

Q4 2005

 

% Change

 

 

 

 

 

 

 

 

 

 

 

USD m

 

% of
net sales

 

USD m

 

% of
net sales

 

USD

 

lc

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net sales

 

10 053

 

 

 

8 657

 

 

 

16

 

12

 

Operating income

 

1 824

 

18.1

 

1 488

 

17.2

 

23

 

 

 

Net income

 

1 663

 

16.5

 

1 352

 

15.6

 

23

 

 

 

Basic earnings per share/ADS

 

USD

0.70

 

 

 

USD

0.58

 

 

 

21

 

 

 

 

All product names appearing in italics are trademarks owned by or licensed to Novartis Group Companies

 



 

Basel, January 18, 2007– Commenting on the results, Dr. Daniel Vasella, Chairman and CEO of Novartis, said, “The strong performance in 2006 stems from our commitment to innovation and reflects the impact of strengthening our healthcare portfolio. All divisions, particularly Pharmaceuticals, performed very well. I also have high expectations for further dynamic growth in our new Vaccines and Diagnostics Division. Launches are planned for several innovative medicines in 2007 and 2008, and we will keep investing aggressively in Research & Development to sustain our performance. I am confident of another year of record sales and earnings in 2007.”

 

2006 net sales

 

 

 

2006

 

2005

 

% Change

 

 

 

 

 

 

 

 

 

 

 

USD m

 

USD m

 

USD

 

lc

 

 

 

 

 

 

 

 

 

 

 

Pharmaceuticals

 

22 576

 

20 262

 

11

 

11

 

Vaccines and Diagnostics

 

956

 

 

 

 

 

 

 

Sandoz

 

5 959

 

4 694

 

27

 

25

 

Consumer Health continuing operations

 

6 540

 

6 049

 

8

 

8

 

Net sales from continuing operations

 

36 031

 

31 005

 

16

 

16

 

Consumer Health discontinuing operations

 

989

 

1 207

 

-18

 

-18

 

Total

 

37 020

 

32 212

 

15

 

14

 

 

Group net sales advance 15% (+14% lc) to USD 37.0 billion

Dynamic 2006 Group performance with 15% net sales growth from the strong business expansion in all divisions as well as contributions from recent acquisitions. Higher sales volumes added six percentage points to Group net sales growth and acquisitions seven percentage points, while net price changes and currency translations each led to an increase of one percentage point.

 

Pharmaceuticals net sales up 11% (+11% lc) to USD 22.6 billion

Pharmaceuticals delivered its sixth consecutive year of market share gains and double-digit net sales growth, reaching 11%. The Cardiovascular and Oncology franchises provided dynamic performances as Diovan (+15% lc) exceeded USD 4 billion and Gleevec/Glivec (+17% lc) topped USD 2.5 billion. New product launches, particularly Xolair, Exjade and Prexige, supported the performance. US net sales were up 17%, outpacing the market.

 

Vaccines and Diagnostics net sales of USD 956 million

The turnaround of the influenza vaccine business led the performance. This new division, created from the Chiron acquisition in April 2006, increased net sales 42% in the eight-month period compared to the same period in 2005 reported by Chiron. Diagnostics products, primarily used for testing blood donations, showed continued good growth.

 

Sandoz net sales rise 27% (+25% lc) to USD 6.0 billion

Net sales advanced 27% thanks to strengthening positions in fast-growing generics markets, especially in Europe, as well as successful new product launches, many of which are difficult-to-make products. Also supporting growth were the Hexal and Eon Labs acquisitions.

 

Consumer Health continuing operations net sales up 8% (+8% lc) to USD 6.5 billion

Net sales were driven by double-digit expansions in the OTC and Animal Health businesses, which improved their global rankings thanks to their focus on strategic brands.

 

Consumer Health discontinuing operations net sales of USD 989 million

Consumer Health discontinuing operations reflects net sales of the Medical Nutrition business, which is being sold to Nestlé, as well as the contribution of the Nutrition & Santé business before its divestment in February 2006.

 

2



 

2006 operating income

 

 

 

2006

 

2005

 

Change

 

 

 

 

 

 

 

 

 

 

 

USD m

 

% of
net
sales

 

USD m

 

% of
net
sales

 

In %

 

 

 

 

 

 

 

 

 

 

 

 

 

Pharmaceuticals

 

6 703

 

29.7

 

6 014

 

29.7

 

11

 

Vaccines and Diagnostics

 

-26

 

 

 

 

 

 

 

 

 

Sandoz

 

736

 

12.4

 

342

 

7.3

 

115

 

Consumer Health continuing operations

 

1 068

 

16.3

 

952

 

15.7

 

12

 

Corporate income & expense, net

 

-532

 

 

 

-506

 

 

 

 

 

Operating income from continuing operations

 

7 949

 

22.1

 

6 802

 

21.9

 

17

 

Consumer Health discontinuing operations

 

225

 

22.8

 

103

 

8.5

 

118

 

Total

 

8 174

 

22.1

 

6 905

 

21.4

 

18

 

 

Group operating income rises 18% to USD 8.2 billion

Operating income rose at a faster rate than net sales as the operating margin rose 0.7 percentage points to 22.1%. The organic expansion in Pharmaceuticals, Sandoz and Consumer Health (continuing operations) more than offset the impact of the Chiron acquisition costs of USD 642 million. Excluding these costs, operating income was up 28%.

 

Pharmaceuticals operating income rises 11% to USD 6.7 billion

Organic operating income (excluding Chiron acquisition costs of USD 309 million) advanced 17% and the corresponding operating margin reached 30.4%. The strong business expansion and productivity gains from good cost management more than offset marketing investments to support planned multiple new product launches, particularly in the US, as well as lower divestment income compared to 2005. On a reported basis, operating income grew roughly in line with net sales.

 

Vaccines and Diagnostics operating loss of USD 26 million

The new division had organic operating income of USD 307 million, underpinned by the dynamic increase in net sales of influenza vaccines in the US. This strong performance was more than offset by acquisition-related costs totaling USD 333 million for a reported operating loss of USD 26 million.

 

Sandoz operating income up 115% to USD 736 million

Operating income more than doubled thanks to new product launches, strengthening positions in leading markets and contributions from the Hexal and Eon Labs acquisitions. Operational improvements were made in both the retail generics and anti-infectives businesses. The year-ago period also included acquisition-related costs.

 

Operating income from Consumer Health continuing operations up 12% at USD 1.1 billion

OTC and Animal Health drove the improvement in Consumer Health continuing operations, with both business units delivering strong performances and benefits from high volume gains. However, CIBA Vision had a weak performance due to product supply issues.

 

Consumer Health discontinuing operations operating income of USD 225 million

The reported operating income of USD 225 million for Consumer Health discontinuing operations was supported by a one-time gain of USD 129 million from the divestment of Nutrition & Santé in February 2006.

 

3



 

Fourth quarter 2006 net sales

 

 

 

Q4 2006

 

Q4 2005

 

% Change

 

 

 

 

 

 

 

 

 

 

 

USD m

 

USD m

 

USD

 

lc

 

 

 

 

 

 

 

 

 

 

 

Pharmaceuticals

 

6 049

 

5 248

 

15

 

12

 

Vaccines and Diagnostics

 

455

 

 

 

 

 

 

 

Sandoz

 

1 653

 

1 573

 

5

 

0

 

Consumer Health continuing operations

 

1 644

 

1 551

 

6

 

3

 

Net sales from continuing operations

 

9 801

 

8 372

 

17

 

13

 

Consumer Health discontinuing operations

 

252

 

285

 

-12

 

-14

 

Total

 

10 053

 

8 657

 

16

 

12

 

 

Group net sales rise 16% (+12% lc) to USD 10.1 billion

All divisions underpinned the strong expansion, particularly Pharmaceuticals as net sales of many top-selling products grew at double-digit rates. Higher sales volumes generated eight percentage points of net sales growth, while acquisitions added five and currency translation provided four. Net price changes led to a decline of one percentage point.

 

Pharmaceuticals net sales grow 15% (+12% lc) to USD 6.0 billion

The top selling brands Diovan, Gleevec/Glivec and Lotrel all advanced at double-digit rates. US sales expanded 17% as several products benefited from new clinical data, disease awareness programs and strong positions in Medicare government formularies. Diovan (+13% lc) and Lotrel (+19% lc) led the 13% rise in Cardiovascular strategic brand sales to USD 1.7 billion. Oncology net sales advanced 20% to USD 1.6 billion underpinned by Gleevec/Glivec (+14% lc) and Femara (+35% lc). Russia and Turkey supported the performance in Europe, where net sales rose 18% (+10% lc) and helped to offset weaker performances in France and Germany. In Latin America, net sales were up 16% (+14% lc) thanks to operations in Brazil and Mexico, supported by successful launches of Prexige.

 

Vaccines and Diagnostics net sales of USD 455 million

The ongoing improvement in seasonal influenza vaccine deliveries to the US was the primary growth driver, with net sales up 71% on a comparable basis to the 2005 period reported by Chiron. The diagnostics business improved thanks to continued geographic expansion of nucleic blood testing products and higher sales of West Nile Virus tests in the US.

 

Sandoz net sales up 5% (+0% lc) to USD 1.7 billion

The 2005 fourth quarter included four months of net sales from the Eon Labs acquisition. On a comparable basis, net sales grew 8% (+3% lc) thanks to leading performances in Eastern Europe, Scandinavia, Canada, Switzerland and Australia. Volume gains were seen in Germany from recently launched products that more than offset price cuts. Several new products were launched in the US late in the fourth quarter.

 

Consumer Health continuing operations net sales up 6% (+3% lc) to USD 1.6 billion

The continuing operations of Consumer Health performed well thanks to double-digit growth in Animal Health and OTC that offset a weak performance in CIBA Vision related to a contact lens product recall.

 

4



 

Fourth quarter 2006 operating income

 

 

 

Q4 2006

 

Q4 2005

 

Change

 

 

 

 

 

 

 

 

 

 

 

USD m

 

% of
net
sales

 

USD m

 

% of
net
sales

 

In %

 

 

 

 

 

 

 

 

 

 

 

 

 

Pharmaceuticals

 

1 621

 

26.8

 

1 358

 

25.9

 

19

 

Vaccines and Diagnostics

 

2

 

0.4

 

 

 

 

 

 

 

Sandoz

 

204

 

12.3

 

119

 

7.6

 

71

 

Consumer Health continuing operations

 

143

 

8.7

 

173

 

11.2

 

-17

 

Corporate income & expense, net

 

-176

 

 

 

-179

 

 

 

 

 

Operating income from continuing operations

 

1 794

 

18.3

 

1 471

 

17.6

 

22

 

Consumer Health discontinuing operations

 

30

 

11.9

 

17

 

6.0

 

76

 

Total

 

1 824

 

18.1

 

1 488

 

17.2

 

23

 

 

Group operating income advances 23% to USD 1.8 billion

Operating income rose at a strong pace as Pharmaceuticals and Sandoz delivered excellent performances that included operational improvements and contributions from new product launches.

 

Pharmaceuticals operating income up 19% to USD 1.6 billion

Operating income expanded faster than net sales, even including acquisition-related charges of USD 73 million, thanks to strong performance of leading brands. Marketing & Sales expenses rose 19%, supporting pre-launch investments for anticipated US approvals in 2007 for Galvus (diabetes) and Tekturna/Rasilez, and also the launch of Exforge (hypertension). Other Operating Income & Expenses was higher due to Chiron acquisition costs as well as lower divestment gains compared to 2005. Excluding these acquisition costs, operating income advanced 25% and the operating margin was 28%.

 

Vaccines and Diagnostics generates operating income of USD 2 million

The positive performance reflected organic operating income of USD 109 million that more than offset acquisition-related costs of USD 107 million thanks to the ongoing turnaround in seasonal influenza vaccine deliveries to the US.

 

Sandoz operating income rises 71% to USD 204 million

Operating income expanded strongly as the retail generics business benefited particularly  from new product launches in key markets and synergies from recent acquisitions. The anti-infectives business delivered strong, double-digit growth in difficult market conditions from cost containment efforts and production efficiency.

 

Operating income from Consumer Health continuing operations down 17% to USD 143 million

OTC led the Division with a strong contribution tied mainly to further market share gains. The Division’s overall performance, however, was negatively impacted by costs related to a contact lens product recall in CIBA Vision.

 

5



 

Corporate

 

Financial income, net

Net financial income fell to USD 88 million in 2006 compared to USD 167 million in 2005, reflecting the drop of USD 3.8 billion in average net liquidity to fund recent acquisitions. Net liquidity was USD 0.7 billion at December 31, 2006, down from USD 2.5 billion at the end of 2005. Net financial income in the fourth quarter was USD 38 million, reflecting good currency and interest rate management.

 

Income from associated companies

For the full year, income from associated companies rose to USD 264 million from USD 193 million, mainly from the Roche investment. The group’s interest in Roche generated income of USD 290 million compared to USD 166 million in 2005, comprised of an estimated 2006 income contribution to Novartis of USD 404 million that was offset by USD 114 million for the amortization of intangible assets. In the fourth quarter, associated companies contributed USD 71 million in income, up from USD 67 million in the year-ago period.

 

Group net income advances 17% to USD 7.2 billion

Group net income grew at a double-digit rate in 2006 as the return on net sales advanced to 19.5% from 19.1% in the year-ago period. The strong underlying business expansion lifted operating income at a faster pace than net sales, even including the impact of Chiron acquisition costs. However, non-operating profits were impacted by lower net financial income. Excluding charges of USD 451 million related to the Chiron acquisition, Group net income for the year was up 25%.

 

Balance sheet

The Group’s equity increased by USD 8.1 billion to USD 41.3 billion at December 31, 2006, compared with USD 33.2 billion at the end of 2005. The increase was due to the higher net income of USD 7.2 billion, an upward net revaluation of USD 0.6 billion for the initial Chiron minority stake, increased equity from share-based compensation of USD 0.5 billion, translation gains of USD 1.5 billion, and a contribution of USD 0.3 billion from other factors. This increase was partially offset by the dividend payment of USD 2.0 billion.

 

Total liquidity amounted to USD 8.0 billion at December 31, 2006, down from USD 10.3 billion at the beginning of the year. The debt/equity ratio at December 31, 2006, was 0.18:1 compared to 0.25:1 a year ago.

 

Total non-current assets rose by USD 10.3 billion to USD 46.7 billion, reflecting the impact of the Chiron and NeuTec acquisitions and the related goodwill, other intangible assets and property, plant & equipment contributions.

 

Novartis did not repurchase any shares in 2006 through its share repurchase program via a second trading line on the SWX Swiss Exchange but sold shares amounting to USD 0.2 billion mainly due to the exercise of share-based compensation to associates.

 

Novartis is one of the few non-financial services companies worldwide to have attained the highest credit ratings from Standard & Poor’s, Moody’s and Fitch, the three benchmark rating agencies. S&P has rated Novartis as AAA for long-term maturities and as A1+ for short-term maturities. Moody’s has rated the Group as Aaa and P1, respectively, while Fitch has rated Novartis as AAA for long-term maturities and as F1+ for short-term maturities.

 

6



 

Cash flow

Cash flow from operating activities from continuing operations increased by USD 0.7 billion to USD 8.7 billion, reflecting the business expansion and strict management of working capital. Cash flow used for investing activities from continuing operations included net investment of USD 4.5 billion to acquire Chiron and NeuTec and USD 0.3 billion for the acquisition of other net assets as well as capital expenditures of USD 1.8 billion. Free cash flow after dividends was USD 4.3 billion, a decline of USD 0.3 billion from the year-ago period as lower net proceeds from asset disposals as well as higher net purchases of intangible assets and capital expenditures offset the improvement in operating cash flow.

 

Proposed 2006 dividend

The Board of Directors has proposed for approval at the next Annual General Meeting on March 6, 2007, a dividend payment of CHF 1.35 per share for 2006, an increase of 17% from the dividend of CHF 1.15 per share paid for 2005. This proposed increase marks the tenth consecutive higher payout per share since the creation of Novartis in December 1996. If approved by shareholders, dividends paid for 2006 on outstanding shares are expected to total USD 2.6 billion. The dividend payout ratio for 2006 will be 36% of Group net income. Based on the year-end 2006 share price of CHF 70.25, the dividend yield is 1.9% compared to 1.7% for 2005. The payment date for the 2006 dividend has been set for March 9, 2007. All issued shares are dividend bearing, with the exception of 224.8 million treasury shares.

 

Strategic healthcare portfolio driving sustained strong performance

Novartis is sharpening its focus on medicines and vaccines, taking steps to strengthen strategic growth platforms aimed at best meeting the needs of patients, physicians and society in a dynamically changing healthcare environment.

 

These activities include innovative pharmaceuticals for human and animal health, vaccines, generics and over-the-counter (OTC) products. Novartis is the only pharmaceutical company with strong positions in these areas.

 

The acquisition of the remaining stake of Chiron Corporation in April 2006 not already held by Novartis led to the creation of the new strategic growth platform in vaccines and molecular diagnostics. Chiron’s pharmaceutical products expanded the offering of products for oncology, respiratory and infectious diseases, while early-stage development compounds strengthened the oncology pipeline.

 

Novartis also announced the signing of an agreement in December 2006 to divest the Medical Nutrition business for USD 2.5 billion to Nestlé after having earlier in 2006 completed the sale of the Nutrition & Santé business for USD 211 million. The divestment of Medical Nutrition is expected to be completed in the second half of 2007. Results of these two businesses, which had comprised the Medical Nutrition Business Unit, have been treated as “discontinuing operations” for 2005 and 2006.

 

Group outlook

(For continuing operations, barring any unforeseen events)

Novartis expects in 2007 another year of record net sales and earnings, preparing for a wave of many new product launches during the next two years. Group net sales are expected to rise in 2007 at a mid- to high-single-digit rate in local currencies and net sales in the Pharmaceuticals Division at a mid-single-digit rate for the year.

 

7



 

Pharmaceutical business and key product highlights

Note: All growth figures refer to full-year 2006 worldwide sales growth in local currencies.

 

Diovan (USD 4.2 billion, +15% lc), the leading angiotensin-receptor blocker by sales worldwide, generated further excellent growth and achieved a record market share in its segment based on new indications, higher-strength doses and strong new efficacy data. In the US, Diovan has benefited from a leading formulary position with healthcare payors. Co-Diovan (combination with a diuretic) was up 19% lc in Europe, reflecting the increased use of combination therapies.

 

Gleevec/Glivec (USD 2.6 billion, +17% lc), a targeted treatment for patients with certain forms of chronic myeloid leukemia (CML) and gastro-intestinal stromal tumors (GIST), expanded at an rapid rate through ongoing penetration of the CML and GIST markets. New landmark data showed nearly 90% of CML patients in a five-year study taking Gleevec/Glivec were still alive after five years. Gleevec/Glivec also received four EU and five US approvals for treating various rare diseases during 2006.

 

Lotrel (USD 1.4 billion, +26% only in US), the leading fixed-dose combination treatment for hypertension in the US since 2002, has delivered strong growth based on new dosing strengths as well as increasing use of multiple therapies to treat hypertension, demographic factors and the impact of US disease awareness campaigns.

 

Zometa (USD 1.3 billion, +4% lc), an intravenous bisphosphonate for patients with bone cancer, was impacted by an overall slowing of the market segment in the US and Europe. However, Zometa has gained market segment share in treating patients with lung and prostate cancer and also benefited from a launch in Japan.

 

Lamisil (USD 978 million, –13% lc), an oral treatment for fungal nail infections, generated higher sales in the US, but this was offset by falling sales in Europe following the entry of generic competition in late 2005. In December 2006, the FDA confirmed the granting of a pediatric extension for Lamisil extending its marketing exclusivity through to June 2007.

 

Femara (USD 719 million, +33% lc), a leading oral treatment for women with hormone-related breast cancer, was a key growth driver due to ongoing market segment share gains. Clinical data has confirmed the benefits of use in women after surgery (adjuvant) as well as after completion of tamoxifen therapy (extended adjuvant). Recent four-year data from a major trial confirmed Femara significantly reduces the risk of breast cancer returning.

 

Zelnorm/Zelmac (USD 561 million, +34% lc), for treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation, has benefited from outstanding US growth due to broader use of the product and ongoing disease awareness programs.

 

Visudyne (USD 354 million, –27% lc), a treatment for the eye disease “wet” age-related macular degeneration, reported a sharp decline in net sales linked to off-label competition in the US and in other key markets, but sales in Japan were higher.

 

Exjade (USD 143 million), the first once-daily oral iron chelator for chronic iron overload, has performed well since its approval in the US and over 70 countries in 2006 as a new treatment for iron overload associated with various blood disorders.

 

Xolair (USD 102 million), for severe allergic asthma, has been launched in over 20 countries following EU approval in October 2005, with approvals now received in over 50 countries. In the US, Novartis co-promotes Xolair with Genentech and shares a portion of operating income. Xolair had 2006 net sales of USD 425 million in the US, resulting in a contribution to Novartis of USD 140 million reported as Other Revenues.

 

8



 

Novartis pipeline and regulatory update

With 138 projects in pharmaceutical development, Novartis has one of the industry’s most promising pipelines amid plans for multiple new product approvals and launches over the next two years. Several of these anticipated approvals are for potentially best-in-class medicines that would advance treatment standards for patients with hypertension, diabetes, cancer and other diseases.

 

Beyond these new launches, a number of key compounds are already in or are moving into pivotal late-stage trials, including FTY720 (multiple sclerosis), QAB149 (chronic obstructive pulmonary disease and asthma), AGO178 (depression), RAD001 (cancer), ABF656 (hepatitis C) and SOM230 (Cushing’s disease).

 

Among the recent developments:

 

                  Exforge(1), a single tablet with the two most prescribed branded anti-hypertension medicines – the angiotensin receptor blocker valsartan and the calcium channel blocker amlodipine – received European Commission approval in January 2007 as well as tentative US and Swiss approvals in December 2006. Exforge is expected to be available in Europe during the first half of 2007 and in the US in late September 2007 after the expiry of market exclusivity and patent protection for amlodipine (Norvasc®).(2)

 

                  Galvus (vildagliptin), seeking approval as a new oral once-daily therapy for patients with type 2 diabetes, was issued a three-month review process extension in November 2006 by the FDA. Results from recent clinical trials were submitted to the FDA involving an additional 1,000 patient-years of treatment experience. The data further supports the proposed once-daily dosing regimen and indications as well as complements the drug’s risk/benefit profile. Galvus has been shown to be as effective as a TZD (thiazolidinedione), another oral anti-diabetic class of medicines, in reducing blood sugar but without the side effects of weight gain, edema or heart failure. Over 7,000 patients have been involved in Galvus clinical trials to date.

 

                  Tekturna/Rasilez(1) (aliskiren), seeking to be first in a new class of antihypertensive agents called direct renin inhibitors, received a three-month FDA regulatory review process extension. This will provide the FDA with time to consider additional data submitted by Novartis in early December. These data come from a study involving 30 healthy volunteers who received Tekturna/Rasilez at the proposed 300 mg once-daily dose for eight weeks to study potential changes of the colonic mucosa. Analysis of the data indicated that Tekturna/Rasilez, which was developed in collaboration with Speedel Pharma AG, did not induce any changes in the mucosal lining of the colon, as evaluated by colonoscopy and biopsies.

 

                  Tasigna(1) (nilotinib) was accepted in late 2006 for both US and EU regulatory review as a new option for patients with resistance and/or intolerance to treatment in certain forms of chronic myeloid leukemia. Phase II registration data, presented in December at the American Society of Hematology annual meeting, showed that Tasigna had impressive efficacy and a manageable safety profile, with patients intolerant to Gleevec/Glivec rarely experiencing the same side-effects on Tasigna. About half of patients treated with Tasigna had significantly reduced or no presence of cells with the defective chromosome that causes this blood cancer. Both Tasigna and Gleevec/Glivec, another Novartis medicine, inhibit Bcr-Abl, the definitive

 


(1)              Brand name awaiting approval by regulatory authorities

(2)              Norvasc® is a trademark of Pfizer Inc.

 

9



 

cause of Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). Tasigna was designed to be a more selective inhibitor of Bcr-Abl and its mutations.

 

                  Lucentis (ranibizumab) is anticipated to receive European Union approval in the coming weeks as a new treatment option for patients with “wet” age-related macular degeneration, a leading cause of blindness in people over age 50. Lucentis was approved in June 2006 in the United States and in August 2006 in Switzerland. Genentech retains the rights to Lucentis in the US.

 

                  Aclasta/Reclast(3) (zoledronic acid) was submitted in late 2006 for approval in the US and EU as a once-yearly bisphosphonate infusion for women with postmenopausal osteoporosis. Phase III data demonstrated high efficacy in reducing the incidence of bone fracture at all common fracture sites in women with this debilitating condition. Aclasta/Reclast has also been submitted for US approval as a treatment of patients with Paget’s disease of the bone, an indication already approved in over 50 countries, including key European markets.

 

                  Prexige(4) (lumiracoxib) is on track for launch in European markets in 2007 and 2008 following the successful completion of the Mutual Recognition Procedure (MRP) in October 2006. Prexige received this important regulatory approval as a new treatment option for patients suffering from osteoarthritic pain of the knee and hip. Resubmission to the FDA for US approval is planned for 2007.

 

                  AGO178 (agomelatine) began Phase III trials in the US at the end of 2006 as a once-daily treatment for patients with major depression. AGO178, which was licensed from Servier and for which Novartis has the US rights, has shown efficacy comparable to current standard antidepressant therapies. This compound potentially offers improved tolerability, including a low propensity to cause sexual dysfunction and weight gain as well as an improvement in the quality of sleep. Servier’s submission for European Union approval was not supported by regulators due to insufficient data. This decision is not expected to have any effect on the development strategy and regulatory process in the US, with submission planned for 2008.

 

                  RAD001 (everolimus), a novel oral inhibitor of the mTOR pathway considered a key target in oncology, has demonstrated broad clinical activity in multiple tumor types at well-tolerated and efficacious doses. A registration program is underway that includes the RADIANT-1 study in chemotherapy-refractory pancreatic islet cell tumors (pICT) and the RECORD-1 study in metastatic renal cell carcinoma. This program will be expanded in 2007 to include registration trials for refractory carcinoid tumors as well as first- and second-line pICT. RAD001 acts by directly inhibiting tumor cell growth as well as by inhibiting the formation of new blood vessels (angiogenesis). The first regulatory submission could be as early as 2008.

 


(3)              The proposed US trade name Reclast is currently under review by the US Food and Drug Administration (FDA).

(4)              The US trade name is currently under review by the FDA.

 

10



 

Disclaimer

This release contains certain forward-looking statements relating to the Group’s business, which can be identified by the use of forward-looking terminology such as “proposed”, “plans”, “expectations”, “planned”, “will”, “confident”, “anticipated”, “expected”, “sharpening its focus”, “aimed at”, “outlook”, “expects”, “preparing”, “pipeline”, “development”, “plans”, “potentially”, “would”, “seeking”, “on track”, “could”, or similar expressions, or by express or implied discussions regarding potential future financial results or sales of new or existing products; potential new products, or potential new indications for existing products, or regarding potential future revenues from such products; or by discussions of strategy, plans, expectations or intentions. Such statements reflect the current views of management with respect to future events and are subject to certain known and unknown risks, uncertainties, assumptions and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that the Group will achieve any particular financial results, or that any particular products will reach any particular sales levels. Neither can there be any guarantee that any new products will be approved for sale in any market, or that any new indications will be approved for existing products in any market, or that they will achieve any particular revenue levels. In particular, management’s expectations could be affected by, among other things, uncertainties involved in the development of new pharmaceutical products, including unexpected clinical trial results; unexpected regulatory actions or delays or government regulation; the Group’s ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing and other political pressures; and other risks and factors referred to in the Group’s current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

 

About Novartis

Novartis AG (NYSE: NVS) is a world leader in offering medicines to protect health, cure disease and improve well-being. Our goal is to discover, develop and successfully market innovative products to treat patients, ease suffering and enhance the quality of life. We are strengthening our medicine-based portfolio, which is focused on strategic growth platforms in innovation-driven pharmaceuticals, high-quality and low-cost generics, human vaccines and leading self-medication OTC brands. Novartis is the only company with leadership positions in these areas. In 2006, the Group’s businesses achieved net sales of USD 37.0 billion and net income of USD 7.2 billion. Approximately USD 5.4 billion was invested in R&D. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 101,000 associates and operate in over 140 countries around the world. For more information, please visit http://www.novartis.com.

 

Further important dates

 

 

March 6, 2007

 

Annual General Meeting

April 23, 2007

 

First quarter 2007 results

July 17, 2007

 

First half and second quarter 2007 results

October 18, 2007

 

Nine-month and third quarter 2007 results

 

11



 

Consolidated income statements (audited)

 

Full year

 

 

 

2006

 

2005

 

Change

 

 

 

 

 

 

 

 

 

 

 

USD m

 

USD m

 

USD m

 

%

 

 

 

 

 

 

 

 

 

 

 

Net sales from continuing operations

 

36 031

 

31 005

 

5 026

 

16

 

Other revenues

 

718

 

314

 

404

 

129

 

Cost of Goods Sold

 

-10 299

 

-8 259

 

-2 040

 

25

 

Of which amortization and impairments of product and patent rights and trademarks

 

-764

 

-421

 

-343

 

81

 

Gross profit

 

26 450

 

23 060

 

3 390

 

15

 

Marketing & Sales

 

-10 454

 

-9 397

 

-1 057

 

11

 

Research & Development

 

-5 349

 

-4 825

 

-524

 

11

 

General & Administration

 

-1 957

 

-1 681

 

-276

 

16

 

Other income & expense

 

-741

 

-355

 

-386

 

109

 

Operating income from continuing operations

 

7 949

 

6 802

 

1 147

 

17

 

Income from associated companies

 

264

 

193

 

71

 

37

 

Financial income

 

354

 

461

 

-107

 

-23

 

Interest expense

 

-266

 

-294

 

28

 

-10

 

Income before taxes from continuing operations

 

8 301

 

7 162

 

1 139

 

16

 

Taxes

 

-1 282

 

-1 090

 

-192

 

18

 

Net income from continuing operations

 

7 019

 

6 072

 

947

 

16

 

Net income from Consumer Health discontinuing operations

 

183

 

69

 

114

 

165

 

Total net income

 

7 202

 

6 141

 

1 061

 

17

 

Attributable to:

 

 

 

 

 

 

 

 

 

Equity holders of Novartis AG

 

7 175

 

6 130

 

1 045

 

17

 

Minority interests

 

27

 

11

 

16

 

145

 

Average number of shares outstanding – Basic (million)

 

2 345.2

 

2 332.8

 

 

 

 

 

Total basic earnings per share (USD)(1)

 

3.06

 

2.63

 

0.43

 

16

 

Average number of shares outstanding – Diluted (million)

 

2 360.5

 

2 342.5

 

 

 

 

 

Total diluted earnings per share (USD)(1)

 

3.04

 

2.62

 

0.42

 

16

 

 


(1)              Earnings per share (EPS) is calculated on the amount of net income attributable to the equity holders of Novartis AG. EPS is also based on total net income including Consumer Health discontinuing operations

 

Consolidated statement of recognized income and expense (audited)

 

Full year

 

 

 

2006

 

2005

 

Change

 

 

 

 

 

 

 

 

 

 

 

USD m

 

USD m

 

USD m

 

 

 

 

 

 

 

 

 

Net income

 

7 202

 

6 141

 

1 061

 

Fair value adjustments on financial instruments

 

94

 

-75

 

169

 

Actuarial gains/losses from defined benefit plans

 

139

 

-400

 

539

 

Additionally recognized amounts by associated companies

 

-76

 

41

 

-117

 

Revaluation of initial minority interests in Chiron

 

592

 

 

 

592

 

Translation effects

 

1 493

 

-1 978

 

3 471

 

Recognized income and expense

 

9 444

 

3 729

 

5 715

 

 

12



 

Consolidated income statements (unaudited)

 

Fourth quarter

 

 

 

Q4 2006

 

Q4 2005

 

Change

 

 

 

 

 

 

 

 

 

 

 

USD m

 

USD m

 

USD m

 

%

 

 

 

 

 

 

 

 

 

 

 

Net sales from continuing operations

 

9 801

 

8 372

 

1 429

 

17

 

Other revenues

 

257

 

96

 

161

 

168

 

Cost of Goods Sold

 

-2 901

 

-2 366

 

-535

 

23

 

Of which amortization and impairments of product and patent rights and trademarks

 

-223

 

-139

 

-84

 

60

 

Gross profit

 

7 157

 

6 102

 

1 055

 

17

 

Marketing & Sales

 

-2 991

 

-2 533

 

-458

 

18

 

Research & Development

 

-1 548

 

-1 466

 

-82

 

6

 

General & Administration

 

-615

 

-492

 

-123

 

25

 

Other income & expense

 

-209

 

-140

 

-69

 

49

 

Operating income from continuing operations

 

1 794

 

1 471

 

323

 

22

 

Income from associated companies

 

71

 

67

 

4

 

6

 

Financial income

 

95

 

110

 

-15

 

-14

 

Interest expense

 

-57

 

-67

 

10

 

-15

 

Income before taxes from continuing operations

 

1 903

 

1 581

 

322

 

20

 

Taxes

 

-264

 

-242

 

-22

 

9

 

Net income from continuing operations

 

1 639

 

1 339

 

300

 

22

 

Net income from Consumer Health discontinuing operations

 

24

 

13

 

11

 

85

 

Total net income

 

1 663

 

1 352

 

311

 

23

 

Attributable to:

 

 

 

 

 

 

 

 

 

Equity holders of Novartis AG

 

1 654

 

1 350

 

304

 

23

 

Minority interests

 

9

 

2

 

7

 

350

 

Average number of shares outstanding – Basic (million)

 

2 348.8

 

2 335.5

 

 

 

 

 

Total basic earnings per share (USD) (1)

 

0.70

 

0.58

 

0.12

 

21

 

Average number of shares outstanding – Diluted (million)

 

2 367.5

 

2 350.1

 

 

 

 

 

Total diluted earnings per share (USD)(1)

 

0.70

 

0.57

 

0.13

 

23

 

 


(1)              Earnings per share (EPS) is calculated on the amount of net income attributable to the equity holders of Novartis AG. EPS is also based on total net income including Consumer Health discontinuing operations

 

Consolidated statement of recognized income and expense (unaudited)

 

Fourth quarter

 

 

 

Q4 2006

 

Q4 2005

 

Change

 

 

 

 

 

 

 

 

 

 

 

USD m

 

USD m

 

USD m

 

 

 

 

 

 

 

 

 

Net income

 

1 663

 

1 352

 

311

 

Fair value adjustments on financial instruments

 

106

 

-51

 

157

 

Actuarial gains from defined benefit plans

 

255

 

114

 

141

 

Additionally recognized amounts by associated companies

 

-9

 

7

 

-16

 

Revaluation of initial minority interests in Chiron

 

-17

 

 

 

-17

 

Translation effects

 

622

 

-227

 

849

 

Recognized income and expense

 

2 620

 

1 195

 

1 425

 

 

13



 

Condensed consolidated balance sheets (audited)

 

 

 

Dec 31,
2006

 

Dec 31,
2005

 

Change

 

 

 

 

 

 

 

 

 

 

 

USD m

 

USD m

 

USD m

 

 

 

 

 

 

 

 

 

Assets

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total non-current assets

 

46 604

 

36 289

 

10 315

 

Current assets

 

 

 

 

 

 

 

Inventories

 

4 498

 

3 725

 

773

 

Trade accounts receivable

 

6 161

 

5 343

 

818

 

Other current assets

 

2 054

 

1 442

 

612

 

Cash, short-term deposits and marketable securities

 

7 955

 

10 933

 

-2 978

 

Total current assets from continuing operations

 

20 668

 

21 443

 

-775

 

Assets related to discontinuing operations

 

736

 

 

 

736

 

Total current assets

 

21 404

 

21 443

 

-39

 

Total assets

 

68 008

 

57 732

 

10 276

 

 

 

 

 

 

 

 

 

Equity and liabilities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total equity

 

41 294

 

33 164

 

8 130

 

Non-current liabilities

 

 

 

 

 

 

 

Financial debts

 

656

 

1 319

 

-663

 

Other non-current liabilities

 

9 824

 

7 921

 

1 903

 

Total non-current liabilities

 

10 480

 

9 240

 

1 240

 

Current liabilities

 

 

 

 

 

 

 

Trade accounts payable

 

2 487

 

1 961

 

526

 

Financial debts and derivatives

 

6 643

 

7 135

 

-492

 

Other current liabilities

 

6 897

 

6 232

 

665

 

Total current liabilities from continuing operations

 

16 027

 

15 328

 

699

 

Liabilities related to discontinuing operations

 

207

 

 

 

207

 

Total current liabilities

 

16 234

 

15 328

 

906

 

Total liabilities

 

26 714

 

24 568

 

2 146

 

Total equity and liabilities

 

68 008

 

57 732

 

10 276

 

 

14



 

Condensed consolidated changes in equity

 

Full year (audited)

 

 

 

2006

 

2005

 

Change

 

 

 

 

 

 

 

 

 

 

 

USD m

 

USD m

 

USD m

 

 

 

 

 

 

 

 

 

Consolidated equity at January 1

 

33 164

 

31 315

 

1 849

 

Recognized income and expense

 

9 444

 

3 729

 

5 715

 

Sale/purchase of treasury shares, net

 

248

 

-245

 

493

 

Share-based compensation

 

506

 

445

 

61

 

Dividends

 

-2 049

 

-2 107

 

58

 

Changes in minorities

 

-19

 

27

 

-46

 

Consolidated equity at December 31

 

41 294

 

33 164

 

8 130

 

 

Fourth quarter (unaudited)

 

 

 

Q4 2006

 

Q4 2005

 

Change

 

 

 

 

 

 

 

 

 

 

 

USD m

 

USD m

 

USD m

 

 

 

 

 

 

 

 

 

Consolidated equity at October 1

 

38 590

 

31 748

 

6 842

 

Recognized income and expense

 

2 620

 

1 195

 

1 425

 

Purchase/sale of treasury shares, net

 

-42

 

36

 

-78

 

Share-based compensation

 

134

 

131

 

3

 

Changes in minorities

 

-8

 

54

 

-62

 

Consolidated equity at December 31

 

41 294

 

33 164

 

8 130

 

 

15



 

Condensed consolidated cash flow statements(audited)

 

Full year

 

 

 

2006

 

2005

 

Change

 

 

 

 

 

 

 

 

 

 

 

USD m

 

USD m

 

USD m

 

 

 

 

 

 

 

 

 

Net income from continuing operations

 

7 019

 

6 072

 

947

 

Reversal of non-cash items

 

 

 

 

 

 

 

Taxes

 

1 282

 

1 090

 

192

 

Depreciation, amortization and impairments

 

2 026

 

1 727

 

299

 

Net financial income

 

-88

 

-167

 

79

 

Other

 

130

 

-179

 

309

 

Net income adjusted for non-cash items

 

10 369

 

8 543

 

1 826

 

Interest and other financial receipts

 

520

 

537

 

-17

 

Interest and other financial payments

 

-281

 

-313

 

32

 

Taxes paid

 

-1 760

 

-1 345

 

-415

 

Cash flow before working capital and provision changes

 

8 848

 

7 422

 

1 426

 

Restructuring payments and other cash payments out of provisions

 

-304

 

-285

 

-19

 

Change in net current assets and other operating cash flow items

 

166

 

838

 

-672

 

Cash flow from operating activities of continuing operations

 

8 710

 

7 975

 

735

 

Investments in property, plant & equipment

 

-1 802

 

-1 157

 

-645

 

Acquisitions/divestments of subsidiaries

 

-4 522

 

-8 536

 

4 014

 

Decrease/increase in marketable securities, intangible and financial assets

 

-251

 

2 244

 

-2 495

 

Cash flow from investing activities of continuing operations

 

-6 575

 

-7 449

 

874

 

Cash flow from financing activities of continuing operations

 

-4 970

 

-270

 

-4 700

 

Cash flow from discontinuing operations

 

308

 

76

 

232

 

Translation effect on cash and cash equivalents

 

25

 

-94

 

119

 

Cash and cash equivalents at year-end for discontinuing operations

 

-4

 

 

 

-4

 

Change in cash and cash equivalents

 

-2 506

 

238

 

-2 744

 

Cash and cash equivalents at January 1

 

6 321

 

6 083

 

238

 

Cash and cash equivalents for continuing operations at December 31

 

3 815

 

6 321

 

-2 506

 

 

16



 

Condensed consolidated cash flow statements (unaudited)

 

Fourth quarter

 

 

 

Q4 2006

 

Q4 2005

 

Change

 

 

 

 

 

 

 

 

 

 

 

USD m

 

USD m

 

USD m

 

 

 

 

 

 

 

 

 

Net income from continuing operations

 

1 639

 

1 339

 

300

 

Reversal of non-cash items

 

 

 

 

 

 

 

Taxes

 

264

 

242

 

22

 

Depreciation, amortization and impairments

 

580

 

679

 

-99

 

Net financial income

 

-38

 

-43

 

5

 

Other

 

42

 

-47

 

89

 

Net income adjusted for non-cash items

 

2 487

 

2 170

 

317

 

Interest and other financial receipts

 

121

 

96

 

25

 

Interest and other financial payments

 

-156

 

-163

 

7

 

Taxes paid

 

-331

 

-378

 

47

 

Cash flow before working capital and provision changes

 

2 121

 

1 725

 

396

 

Restructuring payments and other cash payments out of provisions

 

-106

 

-83

 

-23

 

Change in net current assets and other operating cash flow items

 

352

 

578

 

-226

 

Cash flow from operating activities of continuing operations

 

2 367

 

2 220

 

147

 

Investments in property, plant & equipment

 

-668

 

-411

 

-257

 

Acquisitions/divestments of subsidiaries

 

-14

 

6

 

-20

 

Decrease/increase in marketable securities, intangible and financial assets

 

40

 

-891

 

931

 

Cash flow from investing activities of continuing operations

 

-642

 

-1 296

 

654

 

Cash flow from financing activities of continuing operations

 

-1 939

 

1 795

 

-3 734

 

Cash flow from discontinuing operations

 

40

 

42

 

-2

 

Translation effect on cash and cash equivalents

 

-20

 

28

 

-48

 

Cash and cash equivalents at year-end for discontinuing operations

 

1

 

 

 

1

 

Change in cash and cash equivalents

 

-193

 

2 789

 

-2 982

 

Cash and cash equivalents for continuing operations at October 1

 

4 008

 

3 532

 

476

 

Cash and cash equivalents for continuing operations at December 31

 

3 815

 

6 321

 

-2 506

 

 

17



 

Net sales by Division

 

Full year (audited)

 

 

 

2006

 

2005

 

% Change

 

 

 

 

 

 

 

 

 

 

 

USD m

 

USD m

 

USD

 

lc

 

 

 

 

 

 

 

 

 

 

 

Pharmaceuticals

 

22 576

 

20 262

 

11

 

11

 

Vaccines and Diagnostics

 

956

 

 

 

 

 

 

 

Sandoz

 

5 959

 

4 694

 

27

 

25

 

Consumer Health continuing operations

 

6 540

 

6 049

 

8

 

8

 

Net sales from continuing operations

 

36 031

 

31 005

 

16

 

16

 

Consumer Health discontinuing operations

 

989

 

1 207

 

-18

 

-18

 

Total

 

37 020

 

32 212

 

15

 

14

 

 

Fourth quarter (unaudited)

 

 

 

Q4 2006

 

Q4 2005

 

% Change

 

 

 

 

 

 

 

 

 

 

 

USD m

 

USD m

 

USD

 

lc

 

 

 

 

 

 

 

 

 

 

 

Pharmaceuticals

 

6 049

 

5 248

 

15

 

12

 

Vaccines and Diagnostics

 

455

 

 

 

 

 

 

 

Sandoz

 

1 653

 

1 573

 

5

 

0

 

Consumer Health continuing operations

 

1 644

 

1 551

 

6

 

3

 

Net sales from continuing operations

 

9 801

 

8 372

 

17

 

13

 

Consumer Health discontinuing operations

 

252

 

285

 

-12

 

-14

 

Total

 

10 053

 

8 657

 

16

 

12

 

 

Operating income by Division

 

Full year (audited)

 

 

 

2006

 

2005

 

Change

 

 

 

 

 

 

 

 

 

 

 

USD m

 

% of 
net sales

 

USD m

 

% of 
net 
sales

 

In %

 

 

 

 

 

 

 

 

 

 

 

 

 

Pharmaceuticals

 

6 703

 

29.7

 

6 014

 

29.7

 

11

 

Vaccines and Diagnostics

 

-26

 

 

 

 

 

 

 

 

 

Sandoz

 

736

 

12.4

 

342

 

7.3

 

115

 

Consumer Health continuing operations

 

1 068

 

16.3

 

952

 

15.7

 

12

 

Corporate income & expense, net

 

-532

 

 

 

-506

 

 

 

 

 

Operating income from continuing operations

 

7 949

 

22.1

 

6 802

 

21.9

 

17

 

Consumer Health discontinuing operations

 

225

 

22.8

 

103

 

8.5

 

118

 

Total

 

8 174

 

22.1

 

6 905

 

21.4

 

18

 

 

Fourth quarter (unaudited)

 

 

 

Q4 2006

 

Q4 2005

 

Change

 

 

 

 

 

 

 

 

 

 

 

USD m

 

% of 
net sales

 

USD m

 

% of 
net 
sales

 

In %

 

 

 

 

 

 

 

 

 

 

 

 

 

Pharmaceuticals

 

1 621

 

26.8

 

1 358

 

25.9

 

19

 

Vaccines and Diagnostics

 

2

 

0.4

 

 

 

 

 

 

 

Sandoz

 

204

 

12.3

 

119

 

7.6

 

71

 

Consumer Health continuing operations

 

143

 

8.7

 

173

 

11.2

 

—17

 

Corporate income & expense, net

 

-176

 

 

 

-179

 

 

 

 

 

Operating income from continuing operations

 

1 794

 

18.3

 

1 471

 

17.6

 

22

 

Consumer Health discontinuing operations

 

30

 

11.9

 

17

 

6.0

 

76

 

Total

 

1 824

 

18.1

 

1 488

 

17.2

 

23

 

 

18



 

Consolidated income statements – Divisional segmentation (audited)

 

Full year

 

 

 

 

 

 

 

 

 

Consumer Health

 

 

 

 

 

Consumer Health 

 

 

 

 

 

 

 

Vaccines and 

 

 

 

continuing 

 

 

 

Total continuing

 

discontinuing 

 

 

 

 

 

Pharmaceuticals

 

Diagnostics

 

Sandoz

 

operations

 

Corporate

 

operations

 

operations

 

Total Group

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2006

 

2005

 

2006

 

 

 

2006

 

2005

 

2006

 

2005

 

2006

 

2005

 

2006

 

2005

 

2006

 

2005

 

2006

 

2005

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

USD m

 

USD m

 

USD m

 

 

 

USD m

 

USD m

 

USD m

 

USD m

 

USD m

 

USD m

 

USD m

 

USD m

 

USD m

 

USD m

 

USD m

 

USD m

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net sales to third parties

 

22 576

 

20 262

 

956

 

 

 

5 959

 

4 694

 

6 540

 

6 049

 

 

 

 

 

36 031

 

31 005

 

989

 

1 207

 

37 020

 

32 212

 

Sales to other Divisions

 

162

 

128

 

9

 

 

 

148

 

144

 

39

 

23

 

-358

 

-295

 

 

 

 

 

 

 

 

 

 

 

 

 

Sales of Divisions

 

22 738

 

20 390

 

965

 

 

 

6 107

 

4 838

 

6 579

 

6 072

 

-358

 

-295

 

36 031

 

31 005

 

989

 

1 207

 

37 020

 

32 212

 

Other revenues

 

424

 

253

 

231

 

 

 

24

 

18

 

39

 

43

 

 

 

 

 

718

 

314

 

3

 

 

 

721

 

314

 

Cost of Goods Sold

 

-3 826

 

-3 275

 

-795

 

 

 

-3 420

 

-2 883

 

-2 642

 

-2 374

 

384

 

273

 

-10 299

 

-8 259

 

-516

 

-609

 

-10 815

 

-8 868

 

Of which amortization and impairments of product and patent rights and trademarks

 

-225

 

-195

 

-172

 

 

 

-288

 

-169

 

-79

 

-57

 

 

 

 

 

-764

 

-421

 

-11

 

-11

 

-775

 

-432

 

Gross profit

 

19 336

 

17 368

 

401

 

 

 

2 711

 

1 973

 

3 976

 

3 741

 

26

 

-22

 

26 450

 

23 060

 

476

 

598

 

26 926

 

23 658

 

Marketing & Sales

 

-7 069

 

-6 485

 

-124

 

 

 

-1 061

 

-816

 

-2 200

 

-2 096

 

 

 

 

 

-10 454

 

-9 397

 

-302

 

-405

 

-10 756

 

-9 802

 

Research & Development

 

-4 265

 

-3 972

 

-148

 

 

 

-477

 

-434

 

-288

 

-270

 

-171

 

-149

 

-5 349

 

-4 825

 

-15

 

-21

 

-5 364

 

-4 846

 

General & Administration

 

-703

 

-657

 

-92

 

 

 

-311

 

-270

 

-435

 

-370

 

-416

 

-384

 

-1 957

 

-1 681

 

-50

 

-61

 

-2 007

 

-1 742

 

Other income & expense

 

-596

 

-240

 

-63

 

 

 

-126

 

-111

 

15

 

-53

 

29

 

49

 

-741

 

-355

 

116

 

-8

 

-625

 

-363

 

Of which amortization and impairments of capitalized intangibles included in function costs

 

-119

 

-342

 

 

 

 

 

-38

 

-57

 

-31

 

-24

 

-8

 

-17

 

-196

 

-440

 

-10

 

-10

 

-206

 

-450

 

Operating income

 

6 703

 

6 014

 

-26

 

 

 

736

 

342

 

1 068

 

952

 

-532

 

-506

 

7 949

 

6 802

 

225

 

103

 

8 174

 

6 905

 

Income from associated companies

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

264

 

193

 

 

 

 

 

264

 

193

 

Financial income

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

354

 

461

 

 

 

 

 

354

 

461

 

Interest expense

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

-266

 

-294

 

 

 

 

 

-266

 

-294

 

Income before taxes

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

8 301

 

7 162

 

225

 

103

 

8 526

 

7 265

 

Taxes

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

-1 282

 

-1 090

 

-42

 

-34

 

-1 324

 

-1 124

 

Net income

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

7 019

 

6 072

 

183

 

69

 

7 202

 

6 141

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Additions to:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

- Property, plant and equipment(1)

 

1 135

 

686

 

113

 

 

 

264

 

212

 

222

 

233

 

106

 

32

 

1 840

 

1 163

 

11

 

31

 

1 851

 

1 194

 

- Goodwill and other intangibles(1)

 

351

 

211

 

13

 

 

 

38

 

24

 

177

 

160

 

 

 

 

 

579

 

395

 

1

 

2

 

580

 

397

 

 


(1)  Excluding impact of business acquisitions

 

19



 

Consolidated income statements – Divisional segmentation (unaudited)

 

Fourth quarter

 

 

 

 

 

 

 

 

 

Consumer Health

 

 

 

 

 

Consumer Health 

 

 

 

 

 

 

 

Vaccines and 

 

 

 

continuing 

 

 

 

Total continuing

 

discontinuing 

 

 

 

 

 

Pharmaceuticals

 

Diagnostics

 

Sandoz

 

operations

 

Corporate

 

operations

 

operations

 

Total Group

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Q4 2006

 

Q4 2005

 

Q4 2006

 

 

 

Q4 2006

 

Q4 2005

 

Q4 2006

 

Q4 2005

 

Q4 2006

 

Q4 2005

 

Q4 2006

 

Q4 2005

 

Q4 2006

 

Q4 2005

 

Q4 2006

 

Q4 2005

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

USD m

 

USD m

 

USD m

 

 

 

USD m

 

USD m

 

USD m

 

USD m

 

USD m

 

USD m

 

USD m

 

USD m

 

USD m

 

USD m

 

USD m

 

USD m

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net sales to third parties

 

6 049

 

5 248

 

455

 

 

 

1 653

 

1 573

 

1 644

 

1 551

 

 

 

 

 

9 801

 

8 372

 

252

 

285

 

10 053

 

8 657

 

Sales to other Divisions

 

42

 

29

 

-5

 

 

 

36

 

26

 

6

 

1

 

-79

 

-56

 

 

 

 

 

 

 

 

 

 

 

 

 

Sales of Divisions

 

6 091

 

5 277

 

450

 

 

 

1 689

 

1 599

 

1 650

 

1 552

 

-79

 

-56

 

9 801

 

8 372

 

252

 

285

 

10 053

 

8 657

 

Other revenues

 

160

 

79

 

81

 

 

 

6

 

5

 

10

 

12

 

 

 

 

 

257

 

96

 

1

 

 

 

258

 

96

 

Cost of Goods Sold

 

-1 002

 

-860

 

-356

 

 

 

-933

 

-929

 

-700

 

-628

 

90

 

51

 

-2 901

 

-2 366

 

-129

 

-151

 

-3 030

 

-2 517

 

Of which amortization and impairments of product and patent rights and trademarks

 

-74

 

-68

 

-68

 

 

 

-62

 

-52

 

-19

 

-19

 

 

 

 

 

-223

 

-139

 

-3

 

-3

 

-226

 

-142

 

Gross profit

 

5 249

 

4 496

 

175

 

 

 

762

 

675

 

960

 

936

 

11

 

-5

 

7 157

 

6 102

 

124

 

134

 

7 281

 

6 236

 

Marketing & Sales

 

-2 026

 

-1 706

 

-51

 

 

 

-314

 

-266

 

-600

 

-561

 

 

 

 

 

-2 991

 

-2 533

 

-76

 

-96

 

-3 067

 

-2 629

 

Research & Development

 

-1 213

 

-1 216

 

-62

 

 

 

-135

 

-134

 

-90

 

-72

 

-48

 

-44

 

-1 548

 

-1 466

 

-5

 

-6

 

-1 553

 

-1 472

 

General & Administration

 

-218

 

-183

 

-44

 

 

 

-96

 

-91

 

-131

 

-101

 

-126

 

-117

 

-615

 

-492

 

-13

 

-16

 

-628

 

-508

 

Other income & expense

 

-171

 

-33

 

-16

 

 

 

-13

 

-65

 

4

 

-29

 

-13

 

-13

 

-209

 

-140

 

 

 

1

 

-209

 

-139

 

Of which amortization and impairments of capitalized intangibles included in function costs

 

-54

 

-270

 

 

 

 

 

-12

 

-4

 

-9

 

-2

 

-1

 

-3

 

-76

 

-279

 

-2

 

-2

 

-78

 

-281

 

Operating income

 

1 621

 

1 358

 

2

 

 

 

204

 

119

 

143

 

173

 

-176

 

-179

 

1 794

 

1 471

 

30

 

17

 

1 824

 

1 488

 

Income from associated companies

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

71

 

67

 

 

 

 

 

71

 

67

 

Financial income

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

95

 

110

 

 

 

 

 

95

 

110

 

Interest expense

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

-57

 

-67

 

 

 

 

 

-57

 

-67

 

Income before taxes

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

1 903

 

1 581

 

30

 

17

 

1 933

 

1 598

 

Taxes

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

-264

 

-242

 

-6

 

-4

 

-270

 

-246

 

Net income

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

1 639

 

1 339

 

24

 

13

 

1 663

 

1 352

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Additions to:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

- Property, plant and equipment(1)

 

435

 

286

 

50

 

 

 

89

 

59

 

85

 

49

 

39

 

9

 

698

 

403

 

3

 

7

 

701

 

410

 

- Goodwill and other intangibles(1)

 

74

 

53

 

13

 

 

 

25

 

6

 

16

 

107

 

 

 

 

 

128

 

166

 

1

 

2

 

129

 

168

 

 


(1)  Excluding impact of business acquisitions

 

20



 

Notes to the consolidated financial statements for 2006

 

1. Basis of preparation

 

This consolidated financial information containing condensed financial information for the three-month quarterly and the 12-month periods ended December 31, 2006, has been prepared in accordance with International Accounting Standard 34 “Interim Financial Reporting” and with the accounting policies set out in the 2006 Annual Report, which was published on January 18, 2007.

 

2. Business combinations and other significant transactions

 

The following significant transactions occurred during 2006 and 2005:

 

2006

 

Corporate – Chiron acquisition

On April 19, Chiron shareholders approved the acquisition of the remaining 56% of the shares of Chiron Corporation that Novartis did not already own for USD 48.00 per share. The amount paid for the shares, related options of associates and transaction costs totaled approximately USD 5.7 billion. The transaction was completed on April 20. Novartis has created a new division called Vaccines and Diagnostics consisting of two activities: human vaccines named Novartis Vaccines and a diagnostics activity, which retained Chiron as the name. Chiron’s biopharmaceuticals activities were integrated into the Pharmaceuticals division.

 

For the period from January 1 to the date of acquisition, the prior 44% interest in Chiron has been accounted for using the equity method. From its date of acquisition Chiron has been fully consolidated with its identifiable assets and liabilities being revalued to their fair value at the date of acquisition. The Group’s initial 44% interest in Chiron was also revalued directly into equity by USD 0.6 billion.

 

Pharmaceuticals

As part of the Chiron transaction, Chiron’s pharmaceuticals activities have been integrated into the Pharmaceuticals Division. Included in this portfolio are products for the treatment of cystic fibrosis, renal/skin cancer and skin infections. Chiron’s early-stage research has been incorporated into the Pharmaceuticals Division research unit, the Novartis Institutes for BioMedical Research (NIBR). For the period following the acquisition up to December 31, the income statement and cash flows from Chiron’s pharmaceuticals activities have been consolidated into the Division’s results. Goodwill on this transaction at December 31, 2006, amounted to USD 1.9 billion. This goodwill is provisional pending the finalization of the purchase price allocation, which depends on the outcome of negotiations with Bayer-Schering AG on the rights of each party to regulatory, development, manufacturing and supply agreements for Betaseron and its impact on related intangible and other asset values and the resolution of tax-related uncertainties.

 

21



 

On July 14, Novartis announced that its offer for the UK biopharmaceutical company NeuTec Pharma plc, which is specialized in hospital anti-infectives, became unconditional and the company has been consolidated from this date. Novartis paid a total consideration of USD 606 million (GBP 328 million) to fully acquire the company. NeuTec Pharma plc had no post-acquisition sales, although expenses and cash flows have been consolidated from the acquisition date. Goodwill on this transaction at December 31, 2006 amounted to USD 129 million.

 

Vaccines and Diagnostics

For the period following the Chiron acquisition up to December 31, the income statement and cash flows from the vaccines and diagnostics activities comprise the Division’s results. Goodwill on this transaction at December 31, 2006, amounted to USD 1.1 billion and remains provisional pending the resolution of tax related uncertainties.

 

Consumer Health

On February 17, Novartis announced the completion of the sale of its Nutrition & Santé unit, part of the Medical Nutrition Business Unit, for USD 211 million to ABN AMRO Capital France, resulting in a divestment gain before taxes of USD 129 million.

 

On December 14, Novartis announced its intention to divest the remainder of the Medical Nutrition Business Unit to Nestlé S.A., Switzerland for USD 2.5 billion. This transaction, which is subject to customary regulatory approvals, is expected to be completed in the second half of 2007.

 

The Medical Nutrition Business Unit (including the Nutrition & Santé business divested in February 2006) is disclosed as discontinuing operations in all periods in the Group’s consolidated financial statements.

 

2005

 

Sandoz

On June 6, Novartis completed the 100% acquisition of Hexal AG for USD 5.3 billion in cash, with the results and cash flows consolidated from that date. Goodwill on this transaction at December 31, 2006, amounted to USD 3.7 billion.

 

On July 20, Novartis completed the acquisition of 100% of Eon Labs, Inc. for a total cost of USD 2.6 billion, with the results and cash flows consolidated from that date. Goodwill on this transaction at December 31, 2006, amounted to USD 1.8 billion.

 

Consumer Health

On July 14, the Novartis OTC Business Unit announced the acquisition of the rights to produce and market a portfolio of over-the-counter (OTC) brands from Bristol-Myers Squibb Company sold principally in the US for USD 660 million in cash. The closing date for the main North American product portfolio was August 31, 2005; that for the South American portfolio, September 30, 2005 and for the Europe, Middle East and African portfolio January 6, 2006, with the results and cash flows consolidated from these dates. Goodwill on the transaction at December 31, 2006, amounted to USD 49 million.

 

22



 

3. Principal currency translation rates

 

Full year

 

 

 

Average rates
2006


USD

 

Average rates
2005

USD

 

Period-end rates
Dec 31, 2006

USD

 

Period-end rates
Dec 31, 2005

USD

 

 

 

 

 

 

 

 

 

 

 

1 CHF

 

0.798

 

0.804

 

0.819

 

0.762

 

1 EUR

 

1.256

 

1.245

 

1.317

 

1.186

 

1 GBP

 

1.842

 

1.820

 

1.965

 

1.726

 

100 JPY

 

0.860

 

0.910

 

0.841

 

0.851

 

 

Fourth quarter

 

 

 

Average rates
Q4 2006


USD

 

Average rates
Q4 2005

USD

 

Period-end rates
Dec 31, 2006

USD

 

Period-end rates
Dec 31, 2005

USD

 

 

 

 

 

 

 

 

 

 

 

1 CHF

 

0.810

 

0.768

 

0.819

 

0.762

 

1 EUR

 

1.290

 

1.189

 

1.317

 

1.186

 

1 GBP

 

1.916

 

1.748

 

1.965

 

1.726

 

100 JPY

 

0.850

 

0.853

 

0.841

 

0.851

 

 

4. Condensed consolidated change in liquidity

 

Full year

 

 

 

2006

 

2005

 

Change

 

 

 

 

 

 

 

 

 

 

 

USD m

 

USD m

 

USD m

 

 

 

 

 

 

 

 

 

Change in cash and cash equivalents

 

-2 506

 

238

 

-2 744

 

Change in marketable securities, financial debt and financial derivatives

 

683

 

-4 796

 

5 479

 

Change in net liquidity

 

-1 823

 

-4 558

 

2 735

 

Net liquidity at January 1

 

2 479

 

7 037

 

-4 558

 

Net liquidity from continuing operations at December 31

 

656

 

2 479

 

-1 823

 

Net debt from discontinuing operations at December 31

 

-3

 

 

 

-3

 

Total net liquidity at December 31

 

653

 

2 479

 

-1 826

 

 

Fourth quarter

 

 

 

Q4 2006

 

Q4 2005

 

Change

 

 

 

 

 

 

 

 

 

 

 

USD m

 

USD m

 

USD m

 

 

 

 

 

 

 

 

 

Change in cash and cash equivalents

 

-193

 

2 789

 

-2 982

 

Change in marketable securities, financial debt and financial derivatives

 

1 539

 

-1 355

 

2 894

 

Change in net liquidity

 

1 346

 

1 434

 

-88

 

Net liquidity at October 1

 

-690

 

1 045

 

-1 735

 

Net liquidity from continuing operations at December 31

 

656

 

2 479

 

-1 823

 

Net debt from discontinuing operations at December 31

 

-3

 

 

 

-3

 

Net liquidity at December 31

 

653

 

2 479

 

-1 826

 

 

23



 

5. Legal proceedings update

 

A number of our affiliates are the subject of various legal proceedings that arise from time to time in the ordinary course of business. While we do not believe that any of them will have a material adverse effect on our financial position, litigation is inherently unpredictable and excessive verdicts do occur. As a consequence, we may in the future incur judgments or enter into settlements of claims that could have a material adverse effect on our results of operations in any particular period.

 

Please consult the 2006 Annual Report (note 19 to the Group’s consolidated financial statement) for a summary of major legal proceedings.

 

The following non-exhaustive list reflects recent developments in legal proceedings:

 

Canadian Importation Cases: The court of appeals for the Eighth Circuit affirmed the dismissal by a Minnesota court of an antitrust action filed against Novartis AG alleging that Novartis and other pharmaceutical companies conspired against the importation of cheaper Canadian prescription drugs into the United States. Plaintiffs may appeal the decision to the US Supreme Court until February 28, 2007. In addition, a California court granted a Novartis affiliate’s motion for summary judgment in a separate action involving allegations of price fixing. Plaintiffs have appealed the decision.

 

24



 

6. Significant differences between IFRS and US Generally Accepted Accounting Principles (US GAAP)

 

The Group’s consolidated financial statements have been prepared in accordance with IFRS, which, as applied by the Group, differ in certain significant respects from US GAAP. The effects of the application of US GAAP to net income and equity are set out in the tables below. For further comments regarding the nature of these adjustments, please consult note 33 in the Novartis 2006 Annual Report.

 

 

 

2006

 

2005

 

 

 

 

 

 

 

 

 

USD m

 

USD m

 

 

 

 

 

 

 

Net income from continuing operations under IFRS

 

7 019

 

6 072

 

US GAAP adjustments:

 

 

 

 

 

Available-for-sale securities

 

-114

 

278

 

Inventory impairment reversal

 

103

 

20

 

Associated companies

 

 

 

-6

 

Intangible assets

 

-1 743

 

-1 238

 

Property, plant and equipment

 

58

 

53

 

Pensions and other post-employment benefits

 

-198

 

-181

 

Deferred taxes

 

125

 

178

 

Share-based compensation

 

-5

 

-44

 

Minority interests

 

-27

 

-11

 

Other

 

-68

 

 

 

Net income from continuing operations under US GAAP

 

5 150

 

5 121

 

Net income from discontinuing operations under US GAAP

 

114

 

69

 

Net income under US GAAP

 

5 264

 

5 190

 

 

 

 

 

 

 

Earnings per share under US GAAP

 

 

 

 

 

Continuing operations earnings per share (USD)

 

2.19

 

2.19

 

Discontinuing operations earnings per share (USD)

 

0.05

 

0.03

 

Total earnings per share (USD)

 

2.24

 

2.22

 

Diluted earnings per share under US GAAP (USD)

 

 

 

 

 

Continuing operations diluted earnings per share (USD)

 

2.18

 

2.19

 

Discontinuing operations diluted earnings per share (USD)

 

0.05

 

0.03

 

Total diluted earnings per share (USD)

 

2.23

 

2.22

 

 

 

 

Dec 31, 2006

 

USD m

 

Dec 31, 2005

 

USD m

 

 

 

 

 

 

 

Equity under IFRS

 

41 294

 

33 164

 

US GAAP adjustments:

 

 

 

 

 

Available-for-sale securities

 

-37

 

-24

 

Inventory impairment reversal

 

-11

 

-23

 

Associated companies

 

-307

 

25

 

Intangible assets

 

1 349

 

4 092

 

Property, plant and equipment

 

-436

 

-409

 

Pensions and other post-employment benefits

 

15

 

3 133

 

Deferred taxes

 

130

 

-1 438

 

Share-based compensation

 

-186

 

-96

 

Minority interests

 

-183

 

-174

 

Net assets from discontinuing operations

 

-19

 

50

 

Others

 

61

 

 

 

Total US GAAP adjustments

 

376

 

5 136

 

Equity under US GAAP

 

41 670

 

38 300

 

 

25



 

Supplementary information (unaudited)

 

Free cash flow

 

Full year

 

 

 

2006

 

2005

 

Change

 

 

 

 

 

 

 

 

 

 

 

USD m

 

USD m

 

USD m

 

 

 

 

 

 

 

 

 

Cash flow from continuing operating activities

 

8 710

 

7 975

 

735

 

Purchase of property, plant & equipment

 

-1 802

 

-1 157

 

-645

 

Purchase of intangible and financial assets

 

-1 345

 

-1 140

 

-205

 

Sale of property, plant & equipment, intangible and financial assets

 

719

 

1 030

 

-311

 

Dividends

 

-2 049

 

-2 107

 

58

 

Free cash flow from continuing operations

 

4 233

 

4 601

 

-368

 

Free cash flow from discontinuing operations

 

107

 

72

 

35

 

Total free cash flow

 

4 340

 

4 673

 

-333

 

 

Fourth quarter

 

 

 

Q4 2006

 

Q4 2005

 

Change

 

 

 

 

 

 

 

 

 

 

 

USD m

 

USD m

 

USD m

 

 

 

 

 

 

 

 

 

Cash flow from continuing operating activities

 

2 367

 

2 220

 

147

 

Purchase of property, plant & equipment

 

-667

 

-411

 

-256

 

Purchase of intangible and financial assets

 

-255

 

-396

 

141

 

Sale of property, plant & equipment, intangible and financial assets

 

192

 

161

 

31

 

Free cash flow from continuing operations

 

1 637

 

1 574

 

63

 

Free cash flow from discontinuing operations

 

38

 

36

 

2

 

Total free cash flow

 

1 675

 

1 610

 

65

 

 

Share information

 

 

 

December 31, 2006

 

December 31, 2005

 

 

 

 

 

 

 

Number of shares outstanding (million)

 

2 348.2

 

2 335.9

 

Registered share price (CHF)

 

70.25

 

69.05

 

ADS price (USD)

 

57.44

 

52.48

 

Market capitalization (USD billion)

 

135.1

 

122.9

 

Market capitalization (CHF billion)

 

165.0

 

161.3

 

 

26



 

Impact of intangible asset charges and significant exceptional items (unaudited)

 

Full year

 

 

 

Pharmaceuticals

 

Vaccines and
Diagnostics

 

Sandoz

 

Consumer Health
continuing
operations

 

Corporate

 

Total continuing
operations

 

Consumer Health
discontinuing
operations

 

Total Group

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2006

 

2005

 

2006

 

 

2006

 

2005

 

2006

 

2005

 

2006

 

2005

 

2006

 

2005

 

2006

 

2005

 

2006

 

2005

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

USD m

 

USD m

 

USD m

 

 

USD m

 

USD m

 

USD m

 

USD m

 

USD m

 

USD m

 

USD m

 

USD m

 

USD m

 

USD m

 

USD m

 

USD m

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Reported operating income

 

6 703

 

6 014

 

-26

 

 

736

 

342

 

1 068

 

952

 

-532

 

-506

 

7 949

 

6 802

 

225

 

103

 

8 174

 

6 905

 

Recurring amortization

 

268

 

178

 

172

 

 

279

 

189

 

107

 

81

 

8

 

12

 

834

 

460

 

21

 

21

 

855

 

481

 

Impairments

 

76

 

359

 

 

 

 

47

 

37

 

3

 

 

 

 

 

5

 

126

 

401

 

 

 

 

 

126

 

401

 

Intangible asset charges

 

344

 

537

 

172

 

 

326

 

226

 

110

 

81

 

8

 

17

 

960

 

861

 

21

 

21

 

981

 

882

 

Impairment charges on property, plant & equipment

 

3

 

 

 

7

 

 

 

 

14

 

1

 

 

 

 

 

 

 

11

 

14

 

 

 

 

 

11

 

14

 

Impact of increasing acquisition-related inventory to selling price less distribution margin

 

95

 

 

 

117

 

 

 

 

161

 

 

 

 

 

 

 

 

 

212

 

161

 

 

 

21

 

212

 

182

 

Restructuring and acquisition related integration expenses

 

131

 

 

 

44

 

 

61

 

76

 

 

 

 

 

 

 

 

 

236

 

76

 

 

 

19

 

236

 

95

 

Exceptional restructuring and other acquisition-related integration expenses

 

229

 

 

 

168

 

 

61

 

251

 

1

 

 

 

 

 

 

 

459

 

251

 

 

 

40

 

459

 

291

 

Exceptional gains from divesting subsidiaries and major products

 

-87

 

-231

 

 

 

 

7

 

 

 

 

 

-8

 

 

 

 

 

-80

 

-239

 

-129

 

 

 

-209

 

-239

 

Operating income excluding the above items

 

7 189

 

6 320

 

314

 

 

1 130

 

819

 

1 179

 

1 025

 

-524

 

-489

 

9 288

 

7 675

 

117

 

164

 

9 405

 

7 839

 

 

27



 

Impact of intangible asset charges and significant exceptional items (unaudited)

 

Fourth quarter

 

 

 

Pharmaceuticals

 

Vaccines and
Diagnostics

 

Sandoz

 

Consumer Health
continuing
operations

 

Corporate

 

Total continuing
operations

 

Consumer Health
discontinuing
operations

 

Total Group

 

 

 

Q4 2006

 

Q4 2005

 

Q4 2006

 

 

Q4 2006

 

Q4 2005

 

Q4 2006

 

Q4 2005

 

Q4 2006

 

Q4 2005

 

Q4 2006

 

Q4 2005

 

Q4 2006

 

Q4 2005

 

Q4 2006

 

Q4 2005

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

USD m

 

USD m

 

USD m

 

 

USD m

 

USD m

 

USD m

 

USD m

 

USD m

 

USD m

 

USD m

 

USD m

 

USD m

 

USD m

 

USD m

 

USD m

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Reported operating income

 

1 621

 

1 358

 

2

 

 

204

 

119

 

143

 

173

 

-176

 

-179

 

1 794

 

1 471

 

30

 

17

 

1 824

 

1 488

 

Recurring amortization

 

91

 

45

 

68

 

 

73

 

52

 

26

 

22

 

1

 

2

 

259

 

121

 

5

 

5

 

264

 

126

 

Impairments

 

37

 

293

 

 

 

 

1

 

4

 

2

 

 

 

 

 

 

 

40

 

297

 

 

 

 

 

40

 

297

 

Intangible asset charges

 

128

 

338

 

68

 

 

74

 

56

 

28

 

22

 

1

 

2

 

299

 

418

 

5

 

5

 

304

 

423

 

Impairment charges on property, plant & equipment

 

5

 

-19

 

7

 

 

-7

 

11

 

 

 

 

 

 

 

 

 

5

 

-8

 

 

 

 

 

5

 

-8

 

Impact of increasing acquisition-related inventory to selling price less distribution margin

 

14

 

 

 

24

 

 

 

 

42

 

 

 

 

 

 

 

 

 

38

 

42

 

-3

 

16

 

35

 

58

 

Restructuring and acquisition related integration expenses

 

18

 

 

 

15

 

 

7

 

36

 

 

 

 

 

 

 

 

 

40

 

36

 

 

 

8

 

40

 

44

 

Exceptional restructuring and other acquisition-related integration expenses

 

37

 

-19

 

46

 

 

 

 

89

 

 

 

 

 

 

 

 

 

83

 

70

 

-3

 

24

 

80

 

94

 

Exceptional gains from divesting subsidiaries and major products

 

 

 

 

 

 

 

 

7

 

 

 

 

 

 

 

 

 

 

 

7

 

 

 

 

 

 

 

7

 

 

 

Operating income excluding the above items

 

1 786

 

1 677

 

116

 

 

285

 

264

 

171

 

195

 

-175

 

-177

 

2 183

 

1 959

 

32

 

46

 

2 215

 

2 005

 

 

28



 

Supplementary tables: Full-year 2006 net sales of top 20 pharmaceutical products (unaudited)

 

 

 

 

 

US

 

Rest of world

 

Total

 

 

 

 

 

 

 

 

 

 

 

Brands

 

Therapeutic area

 

USD m

 

% change
in local
currencies

 

USD m

 

% change in
local
currencies

 

USD m

 

in USD

 

% change in
local
currencies

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Diovan/Co-Diovan

 

Hypertension

 

1 858

 

20

 

2 365

 

12

 

4 223

 

15

 

15

 

Gleevec/Glivec

 

Chronic myeloid leukemia

 

630

 

20

 

1 924

 

16

 

2 554

 

18

 

17

 

Lotrel

 

Hypertension

 

1 352

 

26

 

 

 

 

 

1 352

 

26

 

26

 

Zometa

 

Cancer complications

 

696

 

-1

 

587

 

12

 

1 283

 

5

 

4

 

Lamisil (group)

 

Fungal infections

 

574

 

7

 

404

 

-31

 

978

 

-14

 

-13

 

Neoral/Sandimmun

 

Transplantation

 

125

 

-17

 

793

 

-1

 

918

 

-4

 

-4

 

Sandostatin (group)

 

Acromegaly

 

367

 

-2

 

548

 

4

 

915

 

2

 

2

 

Lescol

 

Cholesterol reduction

 

256

 

0

 

469

 

-8

 

725

 

-5

 

-5

 

Trileptal

 

Epilepsy

 

549

 

19

 

172

 

11

 

721

 

17

 

17

 

Femara

 

Breast cancer

 

338

 

40

 

381

 

27

 

719

 

34

 

33

 

Top ten products total

 

 

 

6 745

 

15

 

7 643

 

7

 

14 388

 

10

 

10

 

Voltaren (group)

 

Inflammation/pain

 

8

 

60

 

682

 

0

 

690

 

0

 

1

 

Zelnorm/Zelmac

 

Irritable bowel syndrome

 

488

 

37

 

73

 

20

 

561

 

34

 

34

 

Exelon

 

Alzheimer’s disease

 

187

 

9

 

338

 

12

 

525

 

12

 

11

 

Tegretol (incl. CR/XR)

 

Epilepsy

 

120

 

10

 

271

 

-5

 

391

 

-1

 

-1

 

Visudyne

 

Macular degeneration

 

70

 

-62

 

284

 

-6

 

354

 

-27

 

-27

 

Miacalcic

 

Osteoporosis

 

199

 

-13

 

140

 

3

 

339

 

-7

 

-7

 

Comtan/Stalevo (group)

 

Parkinson’s disease

 

157

 

18

 

182

 

24

 

339

 

22

 

21

 

Foradil

 

Asthma

 

14

 

0

 

317

 

-1

 

331

 

0

 

-1

 

Ritalin/Focalin (group)

 

Attention deficit/hyperactive disorder

 

264

 

47

 

66

 

6

 

330

 

37

 

37

 

Famvir

 

Viral infections

 

166

 

10

 

102

 

-3

 

268

 

6

 

5

 

Top 20 products total

 

8 418

 

14

 

10 098

 

5

 

18 516

 

9

 

9

 

Rest of portfolio

 

1 054

 

43

 

3 006

 

14

 

4 060

 

21

 

21

 

Total Division net sales

 

9 472

 

17

 

13 104

 

7

 

22 576

 

11

 

11

 

 

29



 

Supplementary tables: Fourth quarter 2006 net sales of top 20 pharmaceutical products (unaudited)

 

 

 

 

 

US

 

Rest of world

 

Total

 

 

 

 

 

 

 

 

 

 

 

Brands

 

Therapeutic area

 

USD m

 

% change
in local
currencies

 

USD m

 

% change in
local
currencies

 

USD m

 

in USD

 

% change in
local
currencies

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Diovan/Co-Diovan

 

Hypertension

 

505

 

21

 

647

 

7

 

1 152

 

16

 

13

 

Gleevec/Glivec

 

Chronic myeloid leukemia

 

173

 

13

 

529

 

15

 

702

 

19

 

14

 

Lotrel

 

Hypertension

 

354

 

19

 

 

 

 

 

354

 

19

 

19

 

Zometa

 

Cancer complications

 

174

 

-7

 

165

 

21

 

339

 

8

 

5

 

Lamisil (group)

 

Fungal infections

 

127

 

0

 

99

 

-22

 

226

 

-10

 

-11

 

Neoral/Sandimmun

 

Transplantation

 

31

 

-21

 

209

 

-2

 

240

 

0

 

-5

 

Sandostatin (group)

 

Acromegaly

 

99

 

4

 

146

 

7

 

245

 

9

 

6

 

Lescol

 

Cholesterol reduction

 

61

 

-13

 

118

 

-12

 

179

 

-9

 

-12

 

Trileptal

 

Epilepsy

 

145

 

22

 

44

 

13

 

189

 

20

 

20

 

Femara

 

Breast cancer

 

92

 

37

 

112

 

32

 

204

 

40

 

35

 

Top ten products total

 

 

 

1 761

 

12

 

2 069

 

7

 

3 830

 

12

 

9

 

Voltaren (group)

 

Inflammation/pain

 

2

 

0

 

176

 

1

 

178

 

5

 

2

 

Zelnorm/Zelmac

 

Irritable bowel syndrome

 

132

 

25

 

21

 

23

 

153

 

24

 

24

 

Exelon

 

Alzheimer’s disease

 

49

 

9

 

89

 

8

 

138

 

14

 

9

 

Tegretol (incl. CR/XR)

 

Epilepsy

 

32

 

14

 

72

 

3

 

104

 

8

 

6

 

Visudyne

 

Macular degeneration

 

10

 

-68

 

67

 

-18

 

77

 

-28

 

-33

 

Miacalcic

 

Osteoporosis

 

47

 

-8

 

35

 

-3

 

82

 

-4

 

-6

 

Comtan/Stalevo (group)

 

Parkinson’s disease

 

41

 

14

 

51

 

23

 

92

 

23

 

19

 

Foradil

 

Asthma

 

4

 

33

 

88

 

5

 

92

 

14

 

7

 

Ritalin/Focalin (group)

 

Attention deficit/hyperactive disorder

 

79

 

41

 

17

 

8

 

96

 

33

 

34

 

Famvir

 

Viral infections

 

46

 

12

 

25

 

10

 

71

 

8

 

4

 

Top 20 products total

 

2 203

 

12

 

2 710

 

6

 

4 913

 

12

 

9

 

Rest of portfolio

 

318

 

69

 

818

 

21

 

1 136

 

35

 

32

 

Total Division net sales

 

2 521

 

17

 

3 528

 

9

 

6 049

 

15

 

12

 

 

30



 

Pharmaceutical Division therapeutic area net sales (unaudited)

 

Full year

 

 

 

2006

 

2005

 

Change

 

 

 

 

 

 

 

 

 

 

 

USD m

 

USD m

 

USD (%)

 

 

 

 

 

 

 

 

 

Cardiovascular

 

 

 

 

 

 

 

Strategic franchise products

 

 

 

 

 

 

 

Diovan

 

4 223

 

3 676

 

15

 

Lotrel

 

1 352

 

1 075

 

26

 

Lescol

 

725

 

767

 

-5

 

Other

 

172

 

128

 

34

 

Total strategic franchise products

 

6 472

 

5 646

 

15

 

Mature products

 

648

 

665

 

-3

 

Total Cardiovascular products

 

7 120

 

6 311

 

13

 

 

 

 

 

 

 

 

 

Oncology

 

 

 

 

 

 

 

Strategic franchise products

 

 

 

 

 

 

 

Gleevec/Glivec

 

2 554

 

2 170

 

18

 

Zometa

 

1 283

 

1 224

 

5

 

Sandostatin (group)

 

915

 

896

 

2

 

Femara

 

719

 

536

 

34

 

Exjade

 

143

 

2

 

 

 

Other

 

295

 

268

 

10

 

Total Oncology products

 

5 909

 

5 096

 

16

 

 

 

 

 

 

 

 

 

Neuroscience

 

 

 

 

 

 

 

Strategic franchise products

 

 

 

 

 

 

 

Trileptal

 

721

 

615

 

17

 

Exelon

 

525

 

467

 

12

 

Tegretol (incl. CR/XR)

 

391

 

393

 

-1

 

Other

 

1 020

 

758

 

35

 

Total strategic franchise products

 

2 657

 

2 233

 

19

 

Mature products

 

440

 

476

 

-8

 

Total Neuroscience products

 

3 097

 

2 709

 

14

 

 

 

 

 

 

 

 

 

Respiratory & Dermatology

 

 

 

 

 

 

 

Strategic franchise products

 

 

 

 

 

 

 

Lamisil (group)

 

978

 

1 133

 

-14

 

Foradil

 

331

 

332

 

 

 

Elidel

 

179

 

270

 

-34

 

Xolair

 

102

 

5

 

 

 

Other

 

246

 

53

 

364

 

Total strategic franchise products

 

1 836

 

1 793

 

2

 

Mature products

 

123

 

142

 

-13

 

Total Respiratory & Dermatology products

 

1 959

 

1 935

 

1

 

 

 

 

 

 

 

 

 

Arthritis/Bone/Gastrointestinal/Urinary (ABGU)

 

 

 

 

 

 

 

Strategic franchise products

 

 

 

 

 

 

 

Zelnorm/Zelmac

 

561

 

418

 

34

 

Prexige

 

47

 

8

 

488

 

Other

 

117

 

47

 

149

 

Total strategic franchise products

 

725

 

473

 

53

 

Mature products

 

1 526

 

1 581

 

-3

 

Total ABGU products

 

2 251

 

2 054

 

10

 

 

 

 

 

 

 

 

 

Infectious Diseases, Transplantation & Immunology (IDTI)

 

 

 

 

 

 

 

Neoral/Sandimmun

 

918

 

953

 

-4

 

Other

 

330

 

162

 

104

 

Total strategic franchise products

 

1 248

 

1 115

 

12

 

Mature products

 

266

 

270

 

-1

 

Total IDTI products

 

1 514

 

1 385

 

9

 

 

 

 

 

 

 

 

 

Ophthalmics

 

 

 

 

 

 

 

Visudyne

 

354

 

484

 

-27

 

Other

 

372

 

350

 

6

 

Total Ophthalmics products

 

726

 

834

 

-13

 

 

 

 

 

 

 

 

 

Total strategic franchise products

 

19 573

 

17 190

 

14

 

Total mature products

 

3 003

 

3 134

 

-4

 

Prior-years’ US sales rebate accounting adjustment

 

 

 

-62

 

 

 

Total division net sales

 

22 576

 

20 262

 

11

 

 

31



 

Pharmaceutical therapeutic area net sales (unaudited)

 

Fourth quarter

 

 

 

Q4 2006

 

Q4 2005

 

Change

 

 

 

 

 

 

 

 

 

 

 

USD m

 

USD m

 

USD (%)

 

 

 

 

 

 

 

 

 

Cardiovascular

 

 

 

 

 

 

 

Strategic franchise products

 

 

 

 

 

 

 

Diovan

 

1 152

 

994

 

16

 

Lotrel

 

354

 

297

 

19

 

Lescol

 

179

 

196

 

-9

 

Other

 

47

 

39

 

21

 

Total strategic franchise products

 

1 732

 

1 526

 

13

 

Mature products

 

168

 

158

 

6

 

Total Cardiovascular products

 

1 900

 

1 684

 

13

 

 

 

 

 

 

 

 

 

Oncology

 

 

 

 

 

 

 

Strategic franchise products

 

 

 

 

 

 

 

Gleevec/Glivec

 

702

 

590

 

19

 

Zometa

 

339

 

314

 

8

 

Sandostatin (group)

 

245

 

224

 

9

 

Femara

 

204

 

146

 

40

 

Exjade

 

50

 

2

 

 

 

Other

 

74

 

69

 

7

 

Total Oncology products

 

1 614

 

1 345

 

20

 

 

 

 

 

 

 

 

 

Neuroscience

 

 

 

 

 

 

 

Strategic franchise products

 

 

 

 

 

 

 

Trileptal

 

189

 

157

 

20

 

Exelon

 

138

 

121

 

14

 

Tegretol (incl. CR/XR)

 

104

 

96

 

8

 

Other

 

298

 

204

 

46

 

Total strategic franchise products

 

729

 

578

 

26

 

Mature products

 

110

 

100

 

10

 

Total Neuroscience products

 

839

 

678

 

24

 

 

 

 

 

 

 

 

 

Respiratory & Dermatology

 

 

 

 

 

 

 

Strategic franchise products

 

 

 

 

 

 

 

Lamisil (group)

 

226

 

251

 

-10

 

Foradil

 

92

 

81

 

14

 

Elidel

 

47

 

53

 

-11

 

Xolair

 

35

 

2

 

 

 

Other

 

88

 

14

 

 

 

Total strategic franchise products

 

488

 

401

 

22

 

Mature products

 

32

 

34

 

-6

 

Total Respiratory & Dermatology products

 

520

 

435

 

20

 

 

 

 

 

 

 

 

 

Arthritis/Bone/Gastrointestinal/Urinary (ABGU)

 

 

 

 

 

 

 

Strategic franchise products

 

 

 

 

 

 

 

Zelnorm/Zelmac

 

153

 

123

 

24

 

Prexige

 

18

 

5

 

260

 

Other

 

39

 

20

 

95

 

Total strategic franchise products

 

210

 

148

 

42

 

Mature products

 

390

 

389

 

0

 

Total ABGU products

 

600

 

537

 

12

 

 

 

 

 

 

 

 

 

Infectious Diseases, Transplantation & Immunology

 

 

 

 

 

 

 

Neoral/Sandimmun

 

240

 

241

 

0

 

Other

 

91

 

53

 

72

 

Total strategic franchise products

 

331

 

294

 

13

 

Mature products

 

73

 

86

 

-15

 

Total IDTI products

 

404

 

380

 

6

 

 

 

 

 

 

 

 

 

Ophthalmics

 

 

 

 

 

 

 

Visudyne

 

77

 

107

 

-28

 

Other

 

95

 

82

 

16

 

Total Ophthalmics products

 

172

 

189

 

-9

 

 

 

 

 

 

 

 

 

Total strategic franchise products

 

5 276

 

4 481

 

18

 

Total mature products

 

773

 

767

 

1

 

Total division net sales

 

6 049

 

5 248

 

15

 

 

32



 

Net sales by region (unaudited)

 

Full year

 

 

 

2006

 

2005

 

% change

 

2006

 

2005

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

local

 

 

 

 

 

 

 

USD m

 

USD m

 

USD

 

currencies

 

% of total

 

% of total

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Pharmaceuticals

 

 

 

 

 

 

 

 

 

 

 

 

 

US

 

9 472

 

8 085

 

17

 

17

 

42

 

40

 

Rest of world

 

13 104

 

12 177

 

8

 

7

 

58

 

60

 

Total

 

22 576

 

20 262

 

11

 

11

 

100

 

100

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Vaccines and Diagnostics

 

 

 

 

 

 

 

 

 

 

 

 

 

US

 

462

 

 

 

 

 

 

 

48

 

 

 

Rest of world

 

494

 

 

 

 

 

 

 

52

 

 

 

Total

 

956

 

 

 

 

 

 

 

100

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Sandoz

 

 

 

 

 

 

 

 

 

 

 

 

 

US

 

1 548

 

1 282

 

21

 

21

 

26

 

27

 

Rest of world

 

4 411

 

3 412

 

29

 

27

 

74

 

73

 

Total

 

5 959

 

4 694

 

27

 

25

 

100

 

100

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Consumer Health(1)

 

 

 

 

 

 

 

 

 

 

 

 

 

US

 

3 516

 

3 220

 

9

 

9

 

47

 

44

 

Rest of world

 

4 013

 

4 036

 

-1

 

-1

 

53

 

56

 

Total

 

7 529

 

7 256

 

4

 

3

 

100

 

100

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Group(1)

 

 

 

 

 

 

 

 

 

 

 

 

 

US

 

14 998

 

12 587

 

19

 

19

 

41

 

39

 

Rest of world

 

22 022

 

19 625

 

12

 

11

 

59

 

61

 

Total

 

37 020

 

32 212

 

15

 

14

 

100

 

100

 

 


(1)   Includes both Consumer Health Division continuing and discontinuing operations

 

33



Net sales by region (unaudited)

 

Fourth quarter

 

 

 

Q4 2006

 

Q4 2005

 

% change

 

Q4 2006

 

Q4 2005

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

local

 

 

 

 

 

 

 

USD m

 

USD m

 

USD

 

currencies

 

% of total

 

% of total

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Pharmaceuticals

 

 

 

 

 

 

 

 

 

 

 

 

 

US

 

2 521

 

2 156

 

17

 

17

 

42

 

41

 

Rest of world

 

3 528

 

3 092

 

14

 

9

 

58

 

59

 

Total

 

6 049

 

5 248

 

15

 

12

 

100

 

100

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Vaccines and Diagnostics

 

 

 

 

 

 

 

 

 

 

 

 

 

US

 

230

 

 

 

 

 

 

 

51

 

 

 

Rest of world

 

225

 

 

 

 

 

 

 

49

 

 

 

Total

 

455

 

 

 

 

 

 

 

100

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Sandoz

 

 

 

 

 

 

 

 

 

 

 

 

 

US

 

422

 

458

 

-8

 

-8

 

26

 

29

 

Rest of world

 

1 231

 

1 115

 

10

 

4

 

74

 

71

 

Total

 

1 653

 

1 573

 

5

 

0

 

100

 

100

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Consumer Health(1)

 

 

 

 

 

 

 

 

 

 

 

 

 

US

 

874

 

859

 

2

 

2

 

46

 

47

 

Rest of world

 

1 022

 

977

 

5

 

-1

 

54

 

53

 

Total

 

1 896

 

1 836

 

3

 

0

 

100

 

100

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Group(1)

 

 

 

 

 

 

 

 

 

 

 

 

 

US

 

4 047

 

3 473

 

17

 

17

 

40

 

40

 

Rest of world

 

6 006

 

5 184

 

16

 

10

 

60

 

60

 

Total

 

10 053

 

8 657

 

16

 

12

 

100

 

100

 

 


(1)   Includes both Consumer Health Division continuing and discontinuing operations

 

34



 

Quarterly analysis

 

Key figures by quarter(1)

 

 

 

Q4 2006

 

Q3 2006

 

Change

 

 

 

 

 

 

 

 

 

 

 

USD m

 

USD m

 

USD m

 

%

 

 

 

 

 

 

 

 

 

 

 

Net sales

 

10 053

 

9 484

 

569

 

6

 

Operating income

 

1 824

 

2 088

 

-264

 

-13

 

Financial income

 

95

 

72

 

23

 

32

 

Interest expense

 

-57

 

-76

 

19

 

-25

 

Taxes

 

-264

 

-302

 

38

 

-13

 

Net income

 

1 663

 

1 870

 

-207

 

-11

 

 


(1)   Includes both Consumer Health Division continuing and discontinuing operations

 

Net sales by region(1)

 

 

 

Q4 2006

 

Q3 2006

 

Change

 

 

 

 

 

 

 

 

 

 

 

USD m

 

USD m

 

USD m

 

%

 

 

 

 

 

 

 

 

 

 

 

US

 

4 047

 

3 885

 

162

 

4

 

Europe

 

3 705

 

3 482

 

223

 

6

 

Rest of world

 

2 301

 

2 117

 

184

 

9

 

Total

 

10 053

 

9 484

 

569

 

6

 

 


(1)   Includes both Consumer Health Division continuing and discontinuing operations

 

Net sales by division

 

 

 

Q4 2006

 

Q3 2006

 

Change

 

 

 

 

 

 

 

 

 

 

 

USD m

 

USD m

 

USD m

 

%

 

 

 

 

 

 

 

 

 

 

 

Pharmaceuticals

 

6 049

 

5 776

 

273

 

5

 

Vaccines and Diagnostics

 

455

 

374

 

81

 

22

 

Sandoz

 

1 653

 

1 425

 

228

 

16

 

Consumer Health continuing operations

 

1 644

 

1 654

 

-10

 

-1

 

Net sales from continuing operations

 

9 801

 

9 229

 

572

 

6

 

Consumer Health discontinuing operations

 

252

 

255

 

-3

 

-1

 

Total

 

10 053

 

9 484

 

569

 

6

 

 

Operating income by division

 

 

 

Q4 2006

 

Q3 2006

 

Change

 

 

 

 

 

 

 

 

 

 

 

USD m

 

USD m

 

USD m

 

%

 

 

 

 

 

 

 

 

 

 

 

Pharmaceuticals

 

1 621

 

1 779

 

-158

 

9

 

Vaccines and Diagnostics

 

2

 

10

 

-8

 

-80

 

Sandoz

 

204

 

87

 

117

 

134

 

Consumer Health continuing operations

 

143

 

317

 

-174

 

-55

 

Corporate income & expense, net

 

-176

 

-138

 

-38

 

28

 

Operating income from continuing operations

 

1 794

 

2 055

 

-261

 

-13

 

Consumer Health discontinuing operations

 

30

 

33

 

-3

 

-9

 

Total

 

1 824

 

2 088

 

-264

 

-13

 

 

35



 

SIGNATURES

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, Novartis AG has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

 

 

NOVARTIS AG

 

 

 

 

Date: January 24, 2007

By:

 /s/ MALCOLM CHEETHAM

 

 

 

 

 

Name:

Malcolm Cheetham

 

Title:

Head Group Financial Reporting

 

 

and Accounting